Solitary plasmacytoma: should new approaches in diagnosis and treatment be adopted?
Abstract
Background: Radiotherapy (RT) is the gold standard for solitary plasmacytomas (SP) with great local control. The influence of radiotherapy as well as factors on multiple myeloma (MM) progression is unknown.
Materials and methods: We present a retrospective study of 27 patients with SP (bone-SBP- and extramedullary-SEP-), treated since 1995 to 2021. We aim to analyze prognostic factors affecting local control and progression to MM in patients treated with radiotherapy (RT).
Results: Mean age was 57.3 years. 22 were SBP and 5 SEP. 13 patients were treated with definitive RT, and 14 with a combination of RT and systemic treatment and/or surgery. Local control was observed in 91.5% of cases. 28% experienced progression to MM. With a median follow up of 61.4 months [39.5, 121.6], 5-years MM-free-survival was 81 ± 8%; no individuals progressed further 50 months since diagnosis. Large tumor bulk (> 5 cm) and type (SBP 36% vs. SEP 0%) were associated with progression. Progression was not affected by doses greater than 46 Gy and/or surgery. An immunophenotype different from IgG kappa was predictive of less progression (p = 0.031) in Cox regression analysis adjusted for age, RT dose and tumor bulk > 5 cm. Patients with positron emission tomography-computed tomography (PET-CT) staging showed less MM progression, without statistical differences.
Conclusion: RT achieves more than 90% of local control. The immunophenotype IgG kappa showed more risk of progression to MM. Initial staging with PET-CT seems to lead to a better identification of SP. The inclusion of bad prognosis patients in clinical trials would determine the role of adjuvant chemoimmunotherapy in SP treatment.
Keywords: solitary plasmacytomamultiple myelomaradiotherapyIgG kappaPET-CT
References
- Tsang RW, Campbell BA, Goda JS, et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018; 101(4): 794–808.
- Reed V, Shah J, Medeiros LJ, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011; 117(19): 4468–4474.
- Kosydar S, Gulhane A, Libby E, et al. Radiographic Response of Solitary Plasmacytomas After Conformal Radiotherapy May Be Delayed: Outcomes in the 3D Era. Am J Clin Oncol. 2022; 45(11): 443–449.
- Galieni P, Cavo M, Pulsoni A, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. 2000; 85(1): 47–51.
- Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, et al. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. ScientificWorldJournal. 2012; 2012: 895765.
- Dagan R, Morris CG, Kirwan J, et al. Solitary plasmacytoma. Am J Clin Oncol. 2009; 32(6): 612–617.
- Suh YG, Suh CO, Kim JS, et al. Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors. Ann Hematol. 2012; 91(11): 1785–1793.
- Thumallapally N, Meshref A, Mousa M, et al. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017; 17(1): 13.
- Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006; 64(1): 210–217.
- Liebross RH, Ha CS, Cox JD, et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998; 41(5): 1063–1067.
- Michalaki VJ, Hall J, Henk JM, et al. Definitive radiotherapy for extramedullary plasmacytomas of the head and neck. Br J Radiol. 2003; 76(910): 738–741.
- Soutar R, Lucraft H, Jackson G, et al. Working Group of the UK Myeloma Forum, British Committee for Standards in Haematology, British Society for Haematology. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin Oncol (R Coll Radiol). 2004; 16(6): 405–413.
- Krause S, Hillengass J, Goldschmidt H, et al. Radiotherapy of solitary plasmacytoma. Ann Hematol. 2011; 90(9): 1093–1097.
- Bachar G, Goldstein D, Brown D, et al. Solitary extramedullary plasmacytoma of the head and neck--long-term outcome analysis of 68 cases. Head Neck. 2008; 30(8): 1012–1019.
- Albano D, Tomasini D, Bonù M, et al. F-FDG PET or PET/CT role in plasmacytoma: A systematic review. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020; 39(4): 220–224.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Multiple Myeloma. Version 3-2023. 2022 Dec; In: NCCN.org. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. (23 Dec 2022).
- Schirrmeister H, Buck AK, Bergmann L, et al. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm. 2003; 18(5): 841–845.
- Nanni C, Rubello D, Zamagni E, et al. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008; 22(4): 513–517.
- Kim PJ, Hicks RJ, Wirth A, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2009; 74(3): 740–746.
- Alghisi A, Borghetti P, Maddalo M, et al. Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience. J Cancer Res Clin Oncol. 2021; 147(6): 1773–1779.
- Kilciksiz S, Celik OK, Pak Y, et al. Turkish Oncology Group-Sarcoma Working Party. Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party. Am J Hematol. 2008; 83(9): 702–707.
- Chang WI, Koh HK, Yoon SS, et al. The predictive value of serum myeloma protein in solitary plasmacytoma. Radiat Oncol J. 2020; 38(2): 129–137.
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12): e538–e548.
- Hill QA, Rawstron AC, de Tute RM, et al. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood. 2014; 124(8): 1296–1299.
- Jawad MU, Scully SP. Skeletal Plasmacytoma: progression of disease and impact of local treatment; an analysis of SEER database. J Hematol Oncol. 2009; 2: 41.
- Tsang RW, Gospodarowicz MK, Pintilie M, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001; 50(1): 113–120.
- Mill W, Griffith R. The role of radiation therapy in the management of plasma cell tumors. Cancer. 1980; 45(4): 647–652, doi: 10.1002/1097-0142(19800215)45:4<647::aid-cncr2820450405>3.0.co;2-e.
- Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, et al. Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control. Int J Radiat Oncol Biol Phys. 2006; 64(4): 1013–1017.
- Bataille R, Sany J. Solitary myeloma: Clinical and prognostic features of a review of 114 cases. Cancer. 1981; 48(3): 845–851, doi: 10.1002/1097-0142(19810801)48:3<845::aid-cncr2820480330>3.0.co;2-e.
- Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15): 3412–3420.